Videos

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.

Gomberg-Maitland addresses sotatercept’s capacity to improve pulmonary vascular and cardiac endpoints in patients with CpcPH-HFpEF.

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

Catch up on the most impactful trial readouts to come out of ACC 2026.

This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.

Laffin discusses results from the Kardinal study, which investigated a single dose of tonlamarsen followed by placebo against monthly tonlamarsen treatment in hypertension.

In this AAD interview, Song highlights how he views the potential benefit of amlitelimab in light of discontinuing rocatinlimab.

Song speaks about JAK inhibitors and their safety in dermatology care settings, contextualizing previous data on adverse events.

Nicholls discusses the investigational oral CETP inhibitor’s effects on kidney health for patients at high risk of cardiovascular disease due to elevated HDL-C.

The WHO resolution on kidney health elevates kidney disease as a global health priority, emphasizing early detection, treatment, and system-wide action.

Further CONFIDENCE analyses support safe combination therapy in CKD, with improved responses in key patient subgroups.

An interview with Thase explores rapid antidepressant effects and real-world considerations for single-day individualized GH001 dosing in TRD.

Ackerman offers a broad perspective on how psoriatic treatment is shifting, from oral IL-23 inhibitors to the emerging role of incretin therapy in psoriatic disease.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Eingun James Song, MD, discusses takeaways from his AAD session on addressing concerns of patients with psoriasis and skin of color.

Rossano discusses the results of the phase 3 SCOUT-HCM trial, highlighting mavacamten’s comparative superiority in reducing left ventricular outflow.

Gerlud explains unmet needs in EPI, including underdiagnosed patient populations, and the intense pill burdens patients face.

Analysis of 75,064 UK Biobank participants found late-onset depression associated with worse fluid intelligence and visuospatial memory and a 42–52% increased dementia risk.

In this segment of his interview, Passeron speaks on the next steps for upadacitinib in non-segmental vitiligo (NSV).

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.

Experts reflect on how advances in understanding CLE have fueled drug development and what the trajectory of innovation holds for the field.

Experts share what they anticipate most from the ongoing AMETHYST Phase 3 program and what approval of a first targeted therapy would mean for patients.